Alacrita welcomes Dr David Glover to the team.
David is a highly experienced pharmaceutical physician and company director with particular interest and expertise in the biotech sector. He spent over 10 years at Cambridge Antibody Technology as Chief Medical Officer and previously held senior positions at Merck and Schering Plough.
David’s drug development highlights include widely used small molecule drugs and biologics (enalapril, lisinopril, simvastatin, loratadine, recombinant interferon alfa2b, molgramostim). In addition, David has progressed several human mAbs from preclinical development into man.